Colan Totte.Co.,Ltd. (JP:7792)
:7792
Want to see JP:7792 full AI Analyst Report?
Top Page
Colan Totte.Co.,Ltd.
(7792)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥1,575.00
▲(6.92% Upside)
Action:ReiteratedDate:12/11/25
The overall score of 71 for JP:7792 reflects strong financial performance (score: 83, weight: 0.5) as the primary driver, underpinned by high profitability and a solid balance sheet. Attractive valuation (score: 80, weight: 0.2) adds further support. However, bearish technical indicators (score: 45, weight: 0.3) signal short-term downside risk, tempering the overall outlook.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a strong market position and effective business strategies, supporting long-term expansion and stability.
Negative Factors
Cash Flow Volatility
Volatile cash flow growth can impact the company's ability to invest in new opportunities and manage financial obligations effectively.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates a strong market position and effective business strategies, supporting long-term expansion and stability.
Read all positive factors
Colan Totte.Co.,Ltd. (7792) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥12.44B
Dividend Yield2.9%
Average Volume (3M)17.98K
Price to Earnings (P/E)7.9
Beta (1Y)0.66
Revenue Growth23.51%
EPS Growth0.96%
CountryJP
Employees96
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)46.80
Shares Outstanding9,096,900
10 Day Avg. Volume25,690
30 Day Avg. Volume17,980
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)2.55
Price to Sales (P/S)1.91
P/FCF Ratio18.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Colan Totte.Co.,Ltd. Business Overview & Revenue Model
Company Description
Colan Totte.Co.,Ltd. develops and sells therapy devices under the Colantotte brand in Japan and internationally. The company offers household magnetic therapy devices, such as magnetic necklaces for the neck and shoulders, loop series for the arms...
How the Company Makes Money
Colan Totte Co., Ltd. generates revenue primarily through the sale of its textile products to manufacturers, retailers, and wholesalers both domestically and internationally. The company's revenue model is built on multiple key streams including d...
Colan Totte.Co.,Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
75
Positive
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.92B | 5.94B | 5.41B | 4.66B | 3.71B |
| Gross Profit | 4.66B | 3.97B | 3.45B | 3.04B | 2.46B |
| EBITDA | 1.90B | 1.57B | 1.10B | 1.02B | 691.13M |
| Net Income | 1.33B | 1.02B | 645.02M | 610.45M | 420.50M |
Balance Sheet | |||||
| Total Assets | 6.74B | 5.43B | 4.91B | 4.13B | 3.62B |
| Cash, Cash Equivalents and Short-Term Investments | 2.18B | 1.76B | 1.79B | 1.34B | 1.55B |
| Total Debt | 12.90M | 8.69M | 1.27M | 270.48M | 439.84M |
| Total Liabilities | 1.57B | 1.32B | 1.64B | 1.38B | 1.38B |
| Stockholders Equity | 5.17B | 4.11B | 3.27B | 2.75B | 2.24B |
Cash Flow | |||||
| Free Cash Flow | 728.70M | 357.26M | 867.34M | 75.48M | 597.37M |
| Operating Cash Flow | 998.35M | 883.77M | 955.70M | 148.09M | 637.27M |
| Investing Cash Flow | -303.40M | -736.91M | -83.80M | -80.38M | -51.45M |
| Financing Cash Flow | -272.18M | -180.15M | -410.10M | -274.23M | 452.40M |
Colan Totte.Co.,Ltd. Technical Analysis
Negative
1473.00
Price Trends
1445.10
Negative
1461.43
Negative
1450.53
Negative
Market Momentum
-8.97
Negative
46.60
Neutral
38.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7792, the sentiment is Negative. The current price of 1473 is above the 20-day moving average (MA) of 1400.15, above the 50-day MA of 1445.10, and above the 200-day MA of 1450.53, indicating a neutral trend. The MACD of -8.97 indicates Negative momentum. The RSI at 46.60 is Neutral, neither overbought nor oversold. The STOCH value of 38.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7792.
Colan Totte.Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥10.93B | 44.27 | ― | 3.52% | 4.51% | -11.56% | |
71 Outperform | ¥12.44B | 7.87 | ― | 2.90% | 23.51% | 0.96% | |
68 Neutral | ¥101.87B | 26.70 | ― | 2.31% | 2.68% | 84.62% | |
65 Neutral | ¥241.40B | 36.37 | ― | 1.92% | 2.97% | -26.69% | |
59 Neutral | ¥14.59B | 14.76 | ― | 3.12% | -0.24% | -174.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥126.09B | 28.05 | 2.42% | 3.73% | -0.05% | -40.08% |
* Healthcare Sector Average
JP:7792
Colan Totte.Co.,Ltd.
1,370.00
270.65
24.62%
JP:6523
PHC Holdings Corp.
1,012.00
81.72
8.78%
JP:4549
Eiken Chemical Co., Ltd.
3,105.00
918.00
41.98%
JP:5187
Create Medic Co., Ltd.
1,195.00
291.06
32.20%
JP:6849
Nihon Kohden Corporation
1,461.00
-207.89
-12.46%
JP:7600
Japan Medical Dynamic Marketing, Inc.
503.00
-57.06
-10.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.